Nuclear medicine company Curium plans to acquire Lantheus (LHTN.US) for about $7 billion, and the deal may be officially announced soon

According to WallstreetCN, sources reveal that nuclear medicine company Curium is in advanced negotiations with Lantheus Holdings Inc. (LHTN.US) regarding an acquisition, with the deal potentially being officially announced in the coming days.

Under the proposed terms, Curium, backed by CapVest Partners, plans to pay a cash consideration of approximately $102 per share upfront, along with an additional $12.50 per share in Contingent Value Rights (CVR). Based on this, Lantheus would receive an initial valuation of about $7 billion, rising to $8 billion if the CVR is included. CVRs are additional payments to selling shareholders in M&A transactions, delivered once certain future milestones are achieved.

Sources also cautioned that no final decision has been made, negotiations could still fall apart, and deal terms may be adjusted.

On Monday in the New York market, Lantheus shares closed up 2.1% at $108.03, corresponding to a market value of about $7 billion. The company's market capitalization, headquartered in Bedford, Massachusetts, is roughly in line with this figure.

Curium itself was valued at around $7 billion last year, when CapVest established a continuation vehicle for its nuclear medicine business.

Representatives for Lantheus and Curium both declined to comment, while CapVest did not immediately respond to requests for comment.

Reports in May this year indicated that after receiving an acquisition interest from Curium, Lantheus began evaluating sale options.

Lantheus’s core revenue comes from PYLARIFY—a radiopharmaceutical imaging agent used to detect metastatic prostate cancer. Curium produces radioactive tracers used for diagnosing tumors as well as cardiac, skeletal, and brain diseases.

The two companies had previously announced a licensing and distribution agreement in the European market in 2023.